TABLE 4.
Cox proportional hazards regression analyses of cancer-specific survival (N = 105,394) and overall survival (N = 134,568) for select women with breast cancer in the SEER database from 2004 to 2015
| Cancer-specific survival |
Overall survival |
|||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Group | ||||
| DCISM | -REF- | ** | -REF- | ** |
| DCIS | 0.59 (0.43–0.80) | < 0.001 | 0.84 (0.75–0.93) | 0.001 |
| T1a IDC | 1.43 (1.04–1.98) | 0.03 | 0.98 (0.87–1.09) | 0.66 |
| Grade | ||||
| 1 | -REF- | ** | -REF- | ** |
| 2 | 1.45 (1.19–1.77) | < 0.001 | 1.06 (1.00–1.12) | 0.05 |
| 3 | 2.06 (1.66–2.55) | < 0.001 | 1.09 (1.03–1.16) | 0.005 |
| Unknown | 1.56 (1.21–2.012) | < 0.001 | 1.09 (1.02–1.17) | 0.02 |
| ER | ||||
| Positive | -REF- | -REF- | ** | |
| Negative/borderline | 1.08 (0.87–1.33) | 0.48 | 1.10 (1.02–1.19) | 0.009 |
| Unknown | 1.05 (0.73–1.53) | 0.78 | 1.25 (1.10–1.41) | < 0.001 |
| PR | ||||
| Positive | -REF- | ** | -REF- | |
| Negative/borderline | 1.33 (1.09–1.61) | 0.004 | 1.05 (0.98–1.11) | 0.16 |
| Unknown | 1.25 (0.88–1.78) | 0.21 | 0.92 (0.82–1.04) | 0.18 |
| HER2 | ||||
| Positive | -REF- | -REF- | ||
| Negative/borderline | 1.78 (1.06–2.97) | 0.03 | 1.02 (0.85–1.23) | 0.81 |
| Unknown | 1.27 (0.75–2.16) | 0.37 | 0.96 (0.80–1.15) | 0.68 |
| Diagnosed before 2010* | 1.45 (0.90–2.36) | 0.13 | 1.02 (0.86–1.22) | 0.79 |
| Local-regional treatment | ||||
| Mastectomy alone | -REF- | ** | -REF- | ** |
| Lumpectomy + radiation | 0.61 (0.52–0.70) | < 0.001 | 0.73 (0.69–0.77) | < 0.001 |
| Lumpectomy alone | 1.17 (0.99–1.39) | 0.06 | 1.10 (1.05–1.16) | < 0.001 |
| Mastectomy + radiation | 2.36 (1.73–3.21) | < 0.001 | 1.31 (1.10–1.56) | 0.003 |
| Other/unknown | 1.08 (0.65–1.79) | 0.76 | 0.92 (0.76–1.12) | 0.41 |
| Chemotherapy | ||||
| No/unknown | -REF- | ** | -REF- | ** |
| Yes | 2.58 (2.09–3.20) | < 0.001 | 1.67 (1.51–1.85) | < 0.001 |
Model adjusted for patient age, race/ethnicity, insurance status, and history of other cancers. DCIS ductal carcinoma in situ; DCISM DCIS with microinvasion; IDC invasive ductal carcinoma; ER estrogen receptor; PR progesterone receptor; HER2 human-epidermal-growth-factor-receptor-2
*
Patients diagnosed before 2010 did not routinely have HER2 status reported in the database
**
Overall p value <0.05